Cell & Gene Therapy Jobs UK 2026: The £80k+ Specialism MHRA ATMP Regulation Is Creating

If you have been watching the UK life sciences market in 2026, one corner is moving faster than almost any other: cell and gene therapy (CGT). Demand for CGT scientists, ATMP manufacturing specialists and regulatory affairs leads has outpaced supply for most of the past three years, and a meaningful chunk of senior roles now sit comfortably above £80,000 — with the most specialised crossing £120,000. This guide walks through what the work actually looks like, who is hiring, what the MHRA expects, and how to break in.

The Short Answer

Cell and gene therapy is the branch of biotech that engineers living cells or genetic material to treat disease — CAR-T cancer therapies, in vivo gene replacement, and lentiviral or AAV vector products are the canonical examples. The UK has, by most credible counts, become one of the top three global hubs for the sector, anchored by the Cell and Gene Therapy Catapult, Stevenage Bioscience Catalyst, and a cluster of companies that spun out of Oxford and London academic groups.

Typical 2026 UK pay ranges look roughly like this:

• Entry-level CGT lab roles: around £32,000 to £42,000

• Mid-level CGT scientists and bioprocess engineers: around £48,000 to £72,000

• Senior and principal specialists, QPs and regulatory leads: around £80,000 to £140,000

Top employers actively hiring include Oxford BioMedica, Autolus, Adaptimmune, Achilles Therapeutics, the Cell and Gene Therapy Catapult, GSK at Stevenage, AstraZeneca, and MeiraGTx. The reason pay is climbing is not just demand — it is the regulatory load. The MHRA's Advanced Therapy Medicinal Product (ATMP) framework, and its growing divergence from EMA rules post-Brexit, means CGT companies need staff who can navigate both. That overlap is where the £80k+ specialism is forming.

What Is Cell & Gene Therapy and Why Is the UK a Hub?

Cell and gene therapy covers any therapeutic that delivers its mechanism through genetic material or whole engineered cells rather than a small molecule or recombinant protein. The two architectures most candidates will encounter are autologous therapies — where a patient's own cells are extracted, engineered and reinfused, as with most CAR-T products — and allogeneic therapies, where cells from a donor are engineered and banked to treat many recipients. The autologous model produces high-touch, batch-of-one manufacturing; the allogeneic model looks more like classical biologics scale-up. Both routes have UK champions, and the skills needed differ in important ways.

The UK's hub status is not an accident. Three things appear to have compounded:

1. The Catapult Network. The Cell and Gene Therapy Catapult, headquartered in London with its Manufacturing Innovation Centre in Stevenage, has acted as a shared infrastructure layer — clean rooms, process development, regulatory expertise — that early-stage companies could rent rather than build.

2. The Stevenage Bioscience Catalyst. Sitting alongside the GSK Stevenage campus, the catalyst has become arguably the densest CGT cluster in Europe, with Autolus, Adaptimmune, MeiraGTx and others operating there.

3. An Oxford-Cambridge research base. Oxford BioMedica's viral vector platform and Adaptimmune's TCR work both have deep academic roots, and the Golden Triangle continues to feed the pipeline.

The practical effect for jobseekers is concentration. A serious CGT career path in the UK in 2026 will almost certainly route through Stevenage, Oxford, London or Cambridge at some point — though Edinburgh, Manchester and Cardiff have growing footprints too.

Which Roles Exist Across the CGT Lifecycle?

CGT is unusual in that you can build a long career inside a single therapeutic modality, and the roles are quite structured. The most common job families recruiters fill repeatedly:

• Process Development Scientist (PD). Translates a research-stage process into something manufacturable at scale. Heavy on bioreactors, cell expansion, vector production and analytics. The dominant CGT scientist UK title.

• Upstream / Downstream Bioprocess Specialist. Upstream owns the cell-culture or vector-production stage; downstream owns purification, formulation and fill-finish. Both are highly transferable from monoclonal antibody backgrounds.

• QC Analyst (ATMP). Releases batches against the unusually tight ATMP specifications — potency assays, sterility, identity, vector copy number, residuals. QC in CGT is materially harder than in classical biologics because reference standards often do not exist yet.

• Regulatory Affairs (ATMP). Builds and maintains CTAs, MAAs, IND-equivalents and post-authorisation variations. The MHRA-EMA divergence has roughly doubled the workload here.

• Manufacturing Engineer / MSAT. Owns the GMP suite — equipment qualification, single-use systems, automation, deviations and CAPAs.

• Clinical Trial Manager (Cell Therapy). Coordinates trials where the product itself is the patient's cells, with chain-of-identity and apheresis logistics that traditional CROs are still learning.

• Qualified Person (QP). The legally accountable batch releaser. Eligible QPs with ATMP experience are arguably the single scarcest profile in the UK market right now.

Most companies also hire bioinformaticians, computational biologists and CMC project managers, but the seven families above are where the bulk of advertised vacancies sit.

What Do CGT Roles Pay in the UK?

Salary bands are tightening upward in 2026, particularly for anyone who can credibly claim hands-on ATMP manufacturing UK experience. The numbers below are indicative ranges drawn from advertised vacancies and recruiter benchmarks rather than a single dataset — treat them as a sense-check, not a guarantee.

Two patterns matter. First, regulatory and QP roles now command the top of the table — the direct effect of MHRA ATMP regulation getting more demanding. Second, the spread inside each band is wide because London and Stevenage employers pay a meaningful premium over equivalent roles in Liverpool or Edinburgh.

Top UK Employers Hiring

The CGT hiring market is unusually concentrated. The names below covered the majority of advertised UK CGT vacancies through the first half of 2026:

• Oxford BioMedica (Oxford). Long-standing lentiviral vector specialist, now expanded into a broader CDMO model. Strong on upstream bioprocess and vector analytics.

• Autolus (Stevenage). Commercial-stage CAR-T company. Its purpose-built Stevenage manufacturing facility — reportedly the UK's first commercial cell therapy site at this scale — has been the single largest source of GMP manufacturing roles in the cluster.

• Adaptimmune (Abingdon / Stevenage). TCR-engineered T-cell therapy developer with viral vector capacity inside the CGT Catapult Manufacturing Innovation Centre.

• Achilles Therapeutics (London / Stevenage). Neoantigen-targeted T-cell therapies; tends to recruit heavily in PD and translational science.

• Cell and Gene Therapy Catapult (Stevenage and London). Acts as a training ground for a meaningful share of the wider industry's senior staff.

• GSK (Stevenage). Big-pharma scale CGT programmes co-located with the wider Stevenage campus.

• AstraZeneca (Cambridge). Genomic medicines and gene editing programmes hire across PD, regulatory and clinical operations.

• MeiraGTx (London / Stevenage). AAV gene therapy developer with in-house manufacturing.

Smaller specialists (Quell Therapeutics, Mogrify, Anocca's UK arm) and CDMOs serving the cluster also hire steadily. For early-career candidates, the Catapult and the CDMOs are the most accessible entry points.

MHRA ATMP Regulation: What Engineers and Scientists Need to Know

The MHRA classifies an Advanced Therapy Medicinal Product as a gene therapy, somatic cell therapy, tissue-engineered product or combined ATMP. The framework matters because it dictates what evidence the agency expects, how clean rooms are inspected, and which staff need formal accountability.

A few features tend to surprise candidates moving in from small-molecule or classical biologics:

• The Innovation Office. The MHRA's Innovation Office offers pre-submission engagement that is, in practice, almost obligatory for novel ATMPs. CGT regulatory staff spend a non-trivial share of their time managing that relationship.

• MHRA–EMA divergence post-Brexit. Since the UK left the EMA's centralised procedure, ATMP developers targeting both markets effectively run parallel regulatory tracks. The MHRA has been broadly pragmatic — the ILAP pathway and the new International Recognition Procedure both reduce duplication — but the workload is still meaningfully higher than it was pre-2021.

• GMP for ATMPs. EudraLex Volume 4 Part IV (or its UK-onshored equivalent) imposes specific requirements around starting materials, traceability and chain-of-identity that ordinary biologics GMP does not.

• Qualified Person sign-off. ATMP QPs need additional experience demonstrating ATMP-specific competence; the pool of eligible QPs is small, which is why salaries have moved so sharply.

For engineers and scientists who can credibly demonstrate ATMP-aware practice — and document it on a CV with named products, modalities and regulatory milestones — the premium in 2026 appears to be roughly 15–25% over an equivalent classical biologics role.

How to Break In Without a CGT Background

Most current CGT staff did not start there. Realistic transition routes:

• From classical biologics or mAb manufacturing. Upstream and downstream skills port directly. Focus on roles described as bioprocess or MSAT rather than discovery — your existing GMP exposure is the asset.

• From academic cell biology or virology. PhDs in immunology, virology or stem cell biology are routinely picked up by PD teams. Picking up basic GMP awareness through a short course (e.g. via the Catapult's training programmes) materially lifts your interview rate.

• From pharma regulatory affairs. ATMP regulatory is desperately short of mid-level people. Even six months of shadowing on an ATMP CTA at a CDMO can be enough to reposition.

• From bioprocess engineering more broadly. Single-use systems, automation and bioreactor scale-up experience translate well; the harder gap is usually clean room and aseptic manipulation experience, which you can pick up through an entry GMP operator role.

• From clinical operations. Standard CRO clinical trial managers can step into CGT trials, but should expect to learn apheresis logistics, chain-of-identity and the bedside-to-manufacturing handoff on the job.

A practical heuristic: target the second job, not the first. Many candidates take a deliberate sideways move into a Catapult role or a CDMO operator role for 12 to 24 months, then move into a higher-paid CGT-native role armed with the right vocabulary on the CV.

Frequently Asked Questions: CGT Jobs UK

Do I need a PhD to work in cell and gene therapy in the UK?

No, though it helps for PD and translational roles. Manufacturing, QC, regulatory and clinical operations have well-trodden routes for BSc and MSc holders, and a meaningful share of senior manufacturing staff in Stevenage came up through apprenticeships or BTEC routes.

Where are most UK CGT jobs concentrated?

Stevenage and the wider Hertfordshire cluster, Oxford, London and Cambridge dominate. Edinburgh, Manchester and Cardiff each have a footprint, mostly through academic spin-outs and NHS-linked manufacturing.

What is the difference between an ATMP scientist and a CGT scientist?

In UK practice the two terms are largely interchangeable. ATMP is the regulatory category; CGT is the industry's preferred description. Job adverts use both, sometimes in the same posting.

Are CGT salaries in the UK keeping up with the US?

Not yet — US CGT salaries remain materially higher, particularly in Boston and the Bay Area. But the UK premium over wider biotech has widened in 2026, and the gap between Stevenage and continental Europe has narrowed.

Is CGT manufacturing UK experience portable internationally?

Generally yes. EMA, FDA and MHRA frameworks share enough common ground that experienced ATMP staff move between them. ATMP regulatory affairs is the most jurisdiction-specific specialism — UK-only experience can be a soft constraint in US-headed roles.

How long does it take to qualify as an ATMP QP?

Usually several years on top of an existing science degree, including supervised eligibility experience. Most candidates plan a five- to seven-year arc from joining a QP-track role to formal eligibility.

Summary

Cell and gene therapy is now arguably the highest-leverage specialism inside UK life sciences, both for employers and for candidates. The combination of a dense Stevenage and Oxford employer cluster, an unusually demanding ATMP regulatory framework, and a global shortage of experienced staff has pushed senior pay above £80,000 and, for QPs and regulatory leads, towards £140,000. The route in is no longer reserved for CGT-native PhDs; biologics manufacturing, classical regulatory affairs and even clinical operations all offer realistic on-ramps if you target the second job rather than the first.

Browse current cell and gene therapy jobs across Stevenage, Oxford, London and Cambridge — including ATMP manufacturing, PD scientist and regulatory affairs roles — on biotechnologyjobs.co.uk.